FINWIRES · TerminalLIVE
FINWIRES

自伊朗战争爆发以来,欧洲屋顶太阳能需求翻了一番。

-- 据路透社周四发布的一份分析报告显示,自2月底伊朗战争爆发以来,欧洲家庭对屋顶太阳能的需求增长了一倍多。 伊朗战争推高了石油、天然气和电力价格,使其达到历史新高,迫使人们迅速转向更便宜、更本地化的替代能源,以降低市场极端波动带来的风险。 报告指出,这一激增为这项占欧洲电力总装机容量三分之一的技术带来了至关重要的转机。去年,由于各项扶持政策的到期,屋顶太阳能的新增装机量有所下降。 来自德国、英国和荷兰的行业数据显示,越来越多的房主不再选择简单的太阳能电池板阵列,而是投资包含电池的集成系统。 报告补充说,这些全栈式系统可以将多余的电力存储起来,以便日后使用,从而最大限度地提高能源自给率。 报告还指出,即将出台的立法改革,例如德国修订后的可再生能源法,将进一步推动当前的增长势头。 尽管缺乏完整的 2026 年数据,但据报道需求的增长表明,战争已有效地将住宅太阳能从一种受补贴的奢侈品转变为能源安全的关键工具。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703